Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2002 | 1 |
2010 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Pharmacol Res. 2023 Jul;193:106805. doi: 10.1016/j.phrs.2023.106805. Epub 2023 May 24.
Pharmacol Res. 2023.
PMID: 37236413
Free article.
Review.
We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of long-acting growth hormone (LAGH) vs daily growth hormone (GH) preparations in the treatment of growth hormone deficiency (GHD) in children. ...Adherence and QoL should be …
We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of long-acting growth hormone (LAGH …
Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation.
Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, Milne R.
Bryant J, et al.
Health Technol Assess. 2002;6(19):1-106.
Health Technol Assess. 2002.
PMID: 12583817
Free article.
Review.
No abstract available.
Item in Clipboard
Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, Welch K, Bryant J.
Takeda A, et al.
Health Technol Assess. 2010 Sep;14(42):1-209, iii-iv. doi: 10.3310/hta14420.
Health Technol Assess. 2010.
PMID: 20849734
Free article.
Review.
BACKGROUND: Recombinant human growth hormone (rhGH) is licensed for short stature associated with growth hormone deficiency (GHD), Turner syndrome (TS), Prader-Willi syndrome (PWS), chronic renal insufficiency (CRI), short stature homeobox-containing gene deficiency (SHOX-D) and …
BACKGROUND: Recombinant human growth hormone (rhGH) is licensed for short stature associated with growth hormone deficiency (GHD), Turner sy …
Item in Clipboard
Cite
Cite